iCAD Granted CE Mark Approval in Europe for PowerLook Tomo Detection 2.0 Artificial Intelligence Solution

iCAD (NASDAQ:ICAD), a global leader in medical technology providing innovative cancer detection and therapy solutions, today announced receipt of CE Mark approval for PowerLook Tomo Detection 2.0, the company’s second deep-learning based computer aided detection solution that transforms the way radiologists manage and interpret digital breast tomosynthesis data.  This innovative breast cancer detection solution is compatible with Hologic, GE and Siemens systems.

As quoted in the press release:

“With growing demand for powerful detection and workflow solutions leveraging Artificial Intelligence (AI), especially to assist in cancer detection, we are thrilled to introduce PowerLook Tomo Detection 2.0 to the European market, in addition to making our platform compatible with leading digital breast tomosynthesis providers, including Hologic, GE and Siemens,” said Ken Ferry, CEO of iCAD. “This compatibility considerably increases the market opportunity for iCAD’s AI solutions. Most importantly, both providers and patients alike will now have greater access to one of the most advanced breast cancer detection solutions available in healthcare today.”

Click here to read the full press release.